Celldex Therapeutics, Inc.

CLDX

NASDAQ

Healthcare

Biotechnology

Hampton, NJ, US186 employeescelldex.com

$31.00

-0.27(-0.85%)

Mkt Cap $2.1B

$15.13

$31.80

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Grant (98.7%), Service (1.3%).

8-K

Celldex Therapeutics entered into an underwriting agreement to sell 10,345,000 shares of common stock at $29.00 per share, with expected net proceeds of approximately $282 million, to fund commercial readiness, clinical development, and general corporate purposes.

$2.1B

Market Cap

$2M

Revenue

-$259M

Net Income

Employees186

Fundamentals

How The Business Makes Money

Revenue by Segment

Grant98.7%($30M)

Service1.3%($388.0K)

Activity

What Changed Recently

Material Agreement

Apr 1, 2026

Entry into a Material Definitive Agreement.** On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwri

Financial Results

Feb 24, 2026

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 193

Peer Companies

Company	Price	Change	Market Cap	P/E
VERAVera Therapeutics, Inc.	$40.82	+0.79%	$2.9B	-8.7
SYRESpyre Therapeutics, Inc.	$47.67	-2.52%	$2.9B	-95.3
IMNMImmunome, Inc.	$21.86	-2.63%	$1.9B	-8.5
SIONSionna Therapeutics, Inc.	$40.58	-1.76%	$1.8B	-19.3
HRMYHarmony Biosciences Holdi...	$27.77	-0.68%	$1.6B	10.0
NUVBNuvation Bio Inc.	$4.46	-1.00%	$1.5B	-7.3
ABCLAbCellera Biologics Inc.	$3.54	+0.71%	$1.1B	-6.9
QUREuniQure N.V.	$17.15	+1.55%	$1.1B	-4.6

Analyst View

Company Profile

CIK0000744218

ISINUS15117B2025

CUSIP15117B202

Phone908 200 7500

AddressPerryville III Building, Hampton, NJ, 08827, US

SEC EDGAR